AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27513339 — intervention group
Group type: EXPERIMENTAL
Intervention: Protandim® (1 pill a day for 90 days)
Number of subjects: 38
Study 27513339 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 90 days)
Number of subjects: 38
Study 27513339 — intervention group
Group type: EXPERIMENTAL
Intervention: Protandim® (in subgroup ≥ 35 years)
Number of subjects: 38
Study 27513339 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup ≥ 35 years)
Number of subjects: 38
Study 27513339 — intervention group
Group type: EXPERIMENTAL
Intervention: Protandim®
Number of subjects: 38
Study 27513339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 27513339 — intervention group
Group type: EXPERIMENTAL
Intervention: Protandim® and Placebo
Number of subjects: 38
Study 24344222 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based self-report assessment and educational intervention (screening, targeted education, communication coaching, tracking/graphing SxQOL)
Number of subjects: 752
Study 24344222 — intervention group
Group type: COMPARATOR
Intervention: Control group (SxQOL screening at four time points)
Number of subjects: 752
Study 24344222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Web‐based self-care support and communication coaching)
Number of subjects: 752
Study 22390464 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive reading of food words
Number of subjects: 0
Study 22390464 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive reading of tool words
Number of subjects: 0
Study 22390464 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive reading of object-related nouns
Number of subjects: 0
Study 19800983 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 185
Study 19800983 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 185
Study 19800983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 19800983 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (both doses)
Number of subjects: 185
Study 18381786 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 104
Study 15943653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 38
Study 15943653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (SRT)
Number of subjects: 38
Study 15943653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of CBT and SRT (COMBINED)
Number of subjects: 38
Study 15943653 — intervention group
Group type: COMPARATOR
Intervention: Individual counselling
Number of subjects: 38
Study 12610822 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g lidocaine/prilocaine cream applied to the injection site 60-90 min before the procedure
Number of subjects: 31
Study 12610822 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied to the injection site 60-90 min before the procedure
Number of subjects: 31
Study 10589886 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly sulfadoxine/pyrimethamine
Number of subjects: 120
Study 10589886 — intervention group
Group type: COMPARATOR
Intervention: Daily trimethoprim-sulfamethoxazole
Number of subjects: 120
Study 8694609 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia
Number of subjects: 60
Study 8694609 — intervention group
Group type: COMPARATOR
Intervention: Combined route of delivery (initially antegrade followed by retrograde)
Number of subjects: 60
Study 1746416 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 170
Study 7110969 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/h Risordan intravenously
Number of subjects: 12
Study 7110969 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/h Risordan intravenously
Number of subjects: 12
Study 31345172 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint models analysis
Number of subjects: 0
Study 30107843 — intervention group
Group type: EXPERIMENTAL
Intervention: Our Choice intervention with enhanced training and supervision (SCC1)
Number of subjects: 360
Study 30107843 — intervention group
Group type: EXPERIMENTAL
Intervention: Our Choice intervention implemented by the Ministry of Health's standard approach (SCC2)
Number of subjects: 360
Study 30107843 — intervention group
Group type: COMPARATOR
Intervention: Usual care (existing FP services)
Number of subjects: 360
Study 30107843 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC1 and SCC2
Number of subjects: 360
Study 30107843 — intervention group
Group type: COMPARATOR
Intervention: SCC1, SCC2, and usual care
Number of subjects: 360
Study 27822031 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle stretching combined with aerobic training
Number of subjects: 30
Study 27822031 — intervention group
Group type: COMPARATOR
Intervention: Control group (upper and lower limb muscle stretching)
Number of subjects: 30
Study 24937476 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled IFN‐β (n = 72)
Number of subjects: 147
Study 24937476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 75)
Number of subjects: 147
Study 22578914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 0.5 g/kg per day for 4 consecutive days, given every month for 6 months
Number of subjects: 45
Study 22578914 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone 0.5 g in 250 mL sodium chloride solution per day for 4 consecutive days, given every month for 6 months
Number of subjects: 45
Study 22578914 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 45
Study 22578914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 45
Study 21302708 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive lens exchange with multifocal intraocular lens implantation
Number of subjects: 100
Study 21302708 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK monovision
Number of subjects: 100
Study 17548840 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus oxaliplatin (CAPOX)
Number of subjects: 474
Study 17548840 — intervention group
Group type: COMPARATOR
Intervention: Infusional fluorouracil (FU)/folinic acid plus oxaliplatin (FUFOX)
Number of subjects: 474
Study 15866398 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betamethasone 0.1% cream
Number of subjects: 56
Study 15866398 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 56
Study 11956506 — intervention group
Group type: EXPERIMENTAL
Intervention: SB 249417 (humanized anti-factor IX antibody)
Number of subjects: 26
Study 11956506 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 26
Study 9457933 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 (100 microg/d)
Number of subjects: 28
Study 9457933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9457933 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 28
Study 7620000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG; 750 mg/kg)
Number of subjects: 16
Study 7620000 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG with neutralization titer of > or = 1:800 to the patients' own viral isolates
Number of subjects: 16
Study 2794183 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate group parent training program
Number of subjects: 46
Study 2794183 — intervention group
Group type: COMPARATOR
Intervention: Delayed group parent training program
Number of subjects: 46
Study 22381 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0
Study 22381 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (4 mg)
Number of subjects: 0
Study 22381 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1-2 mg)
Number of subjects: 0
Study 31291683 — intervention group
Group type: EXPERIMENTAL
Intervention: WhiteTeeth mobile app + usual care (n = 67)
Number of subjects: 132
Study 31291683 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (n = 65)
Number of subjects: 132
Study 31148979 — intervention group
Group type: EXPERIMENTAL
Intervention: 600µg of rectal misoprostol
Number of subjects: 122
Study 31148979 — intervention group
Group type: COMPARATOR
Intervention: 20IU of oxytocin infusion
Number of subjects: 122
Study 29144240 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 35
Study 29144240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose
Number of subjects: 35
Study 29144240 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (music + sucrose)
Number of subjects: 35
Study 29144240 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 35
Study 25990055 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium 1 mg/d for 8 weeks
Number of subjects: 40
Study 25990055 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium 2 mg/d for 8 weeks
Number of subjects: 40
Study 25990055 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium (both doses)
Number of subjects: 40
Study 25990055 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 40
Study 23857975 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy before radiation (CT1) - three cycles of cisplatin and etoposide before radiation
Number of subjects: 112
Study 23857975 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy after radiation (RT1) - same chemotherapy regimen after radiation
Number of subjects: 112
Study 21793694 — intervention group
Group type: EXPERIMENTAL
Intervention: Wingate test at 17:00
Number of subjects: 22
Study 21793694 — intervention group
Group type: COMPARATOR
Intervention: Wingate test at 07:00
Number of subjects: 22
Study 19341156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolling Store intervention with nutrition education program
Number of subjects: 40
Study 19341156 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 19341156 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 40
Study 16522905 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-enriched cereal bars (50 mg/d)
Number of subjects: 117
Study 16522905 — intervention group
Group type: COMPARATOR
Intervention: Placebo cereal bars
Number of subjects: 117
Study 12507748 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 45
Study 12507748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11109512 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine (10 mg)
Number of subjects: 40
Study 11109512 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril (5 mg)
Number of subjects: 40
Study 9144764 — intervention group
Group type: EXPERIMENTAL
Intervention: Media-school interventions
Number of subjects: 2860
Study 9144764 — intervention group
Group type: COMPARATOR
Intervention: School interventions only
Number of subjects: 2860
Study 7964942 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial floxuridine (FUDR) 0.30 mg/kg/d, leucovorin (LV) 15 mg/m2/d, dexamethasone (Dec) 20 mg total dose as a 14-day hepatic arterial infusion via an implantable pump alternating with 2 weeks of saline
Number of subjects: 62
Study 7964942 — intervention group
Group type: COMPARATOR
Intervention: Previous trial of hepatic arterial FUDR and LV without Dec
Number of subjects: 62
Study 2891368 — intervention group
Group type: EXPERIMENTAL
Intervention: Temelastine 75 mg twice daily
Number of subjects: 0
Study 2891368 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg twice daily
Number of subjects: 0
Study 2891368 — intervention group
Group type: EXPERIMENTAL
Intervention: Temelastine and Terfenadine
Number of subjects: 0
Study 2891368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31764108 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing offered to adults with symptoms; 1424 referred for testing (37% of symptomatic adults), 1065 accepted testing (75% of those referred).
Number of subjects: 3818
Study 31764108 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing in health facilities.
Number of subjects: 3818
Study 31764108 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing in mobile units.
Number of subjects: 3818
Study 31764108 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting 4-5 symptoms.
Number of subjects: 3818
Study 29051160 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes + no microvascular complication
Number of subjects: 3385
Study 29051160 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes + microvascular complications
Number of subjects: 3385
Study 29051160 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes + no microvascular complication (prior hospitalization for heart failure)
Number of subjects: 3385
Study 29051160 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes + microvascular complications (prior hospitalization for heart failure)
Number of subjects: 3385
Study 26615179 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20mg/day)
Number of subjects: 10576
Study 26615179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10576
Study 24554791 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise program (60-min class twice a week for 16 weeks)
Number of subjects: 49
Study 24554791 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study 21427067 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 50 mg 1 hour prior to oxaliplatin infusion and venlafaxine extended release 37.5 mg b.i.d. from day 2 to day 11
Number of subjects: 48
Study 21427067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 18803639 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended NO analysis
Number of subjects: 89
Study 17470165 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil as needed
Number of subjects: 180
Study 17470165 — intervention group
Group type: COMPARATOR
Intervention: 20 mg paroxetine daily
Number of subjects: 180
Study 17470165 — intervention group
Group type: COMPARATOR
Intervention: Squeeze technique daily
Number of subjects: 180
Study 15316983 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine treatment
Number of subjects: 104
Study 15316983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 11067391 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxybutynin
Number of subjects: 0
Study 11067391 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 0
Study 11067391 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oxybutynin
Number of subjects: 0
Study 9061895 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar voices in a gender judgment task
Number of subjects: 0
Study 9061895 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-modal repetition priming with short SOA
Number of subjects: 0
Study 9061895 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar faces
Number of subjects: 0
Study 9061895 — intervention group
Group type: COMPARATOR
Intervention: Familiar voices and faces
Number of subjects: 0
Study 1327082 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 0
Study 4072874 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiniday, 1200 mg once daily
Number of subjects: 76
Study 4072874 — intervention group
Group type: COMPARATOR
Intervention: Quinidine sulfate (Quinora, 300 mg four times daily)
Number of subjects: 76
Study 4072874 — intervention group
Group type: COMPARATOR
Intervention: Quinidine sulfate (Quinidex Extentabs, 600 mg twice daily)
Number of subjects: 76
Study 4072874 — intervention group
Group type: COMPARATOR
Intervention: Quinidine gluconate (Quinaglute Dura‐Tabs, 648 mg twice daily)
Number of subjects: 76
Study 4072874 — intervention group
Group type: EXPERIMENTAL
Intervention: All quinidine preparations
Number of subjects: 76
Study 2942207 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus a maximally informative booklet (experimental group)
Number of subjects: 63
Study 2942207 — intervention group
Group type: COMPARATOR
Intervention: Routine care plus a minimally informative booklet (placebo group)
Number of subjects: 63
Study 2942207 — intervention group
Group type: COMPARATOR
Intervention: Routine care only (control group)
Number of subjects: 63
Study 29880162 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg Dexamethasone IV drip
Number of subjects: 120
Study 29880162 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg Dexamethasone subcutaneous injection
Number of subjects: 120
Study 29880162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 cc saline infusion)
Number of subjects: 120
Study 28654721 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration with increased infiltration time
Number of subjects: 0
Study 28654721 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration alone
Number of subjects: 0
Study 28654721 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of resin infiltration and bleaching
Number of subjects: 0
Study 28654721 — intervention group
Group type: COMPARATOR
Intervention: In-office bleaching with 35% hydrogen peroxide
Number of subjects: 0
Study 25862762 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF4
Number of subjects: 13
Study 25862762 — intervention group
Group type: EXPERIMENTAL
Intervention: HD8
Number of subjects: 13
Study 25862762 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF8
Number of subjects: 13
Study 23096708 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (Epigallocatechin-3-gallate)
Number of subjects: 0
Study 21918160 — intervention group
Group type: EXPERIMENTAL
Intervention: 30° head-up position
Number of subjects: 20
Study 21918160 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20
Study 18465244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus amoxicillin 1 g b.d. and clarithromycin 500 mg b.d. (RAC group, n = 30)
Number of subjects: 120
Study 18465244 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus moxifloxacine 400 mg o.d. and amoxicillin 1,000 mg b.d. (RAM group, n = 30)
Number of subjects: 120
Study 18465244 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg b.d. plus amoxicillin 1,000 mg b.d. plus moxifloxacine 400 mg o.d. (EAM group, n = 30)
Number of subjects: 120
Study 18465244 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg b.d. plus amoxicillin 1,000 mg b.d. plus clarithromycin 500 mg b.d. (EAC group, n = 30)
Number of subjects: 120
Study 18465244 — intervention group
Group type: COMPARATOR
Intervention: EAM group
Number of subjects: 120
Study 16546738 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline at daily dose of 4 to 6 mg/kg for 16 weeks
Number of subjects: 56
Study 16546738 — intervention group
Group type: COMPARATOR
Intervention: Control group without medication other than beta2 antagonist
Number of subjects: 56
Study 12606523 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 11
Study 12606523 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 11
Study 12606523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10848858 — intervention group
Group type: EXPERIMENTAL
Intervention: Green-hub needle (21 G)
Number of subjects: 98
Study 10848858 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-hub needle (23 G)
Number of subjects: 98
Study 10848858 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-hub needle (23 G) with local anaesthetic
Number of subjects: 98
Study 10848858 — intervention group
Group type: EXPERIMENTAL
Intervention: Green-hub needle (21 G) with local anaesthetic
Number of subjects: 98
Study 9313387 — intervention group
Group type: EXPERIMENTAL
Intervention: Padded, short forearm orthosis
Number of subjects: 42
Study 9313387 — intervention group
Group type: EXPERIMENTAL
Intervention: Two elastic orthoses
Number of subjects: 42
Study 9313387 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer forearm length orthosis
Number of subjects: 42
Study 9313387 — intervention group
Group type: EXPERIMENTAL
Intervention: All three commercial wrist orthoses
Number of subjects: 42
Study 8228078 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/10(4) adrenaline
Number of subjects: 63
Study 8228078 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline plus 1% polidocanol
Number of subjects: 63
Study 3514074 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-field, wedged, inhomogeneous 3-week X-ray treatment followed by two radical radium insertions delivering 80% of a radical intracavity dose
Number of subjects: 296
Study 3514074 — intervention group
Group type: COMPARATOR
Intervention: 4-week homogeneous, large-field X-ray technique supplemented by a single intracavitary insertion giving 50% of a radical intracavitary dose
Number of subjects: 296
Study 29559720 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% sucrose/33% fructose (67%S:33%F)
Number of subjects: 12
Study 29559720 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% sucrose/50% fructose (50%S:50%F)
Number of subjects: 12
Study 29559720 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% sucrose/67% fructose (33%S:67%F)
Number of subjects: 12
Study 29559720 — intervention group
Group type: COMPARATOR
Intervention: 100% sucrose
Number of subjects: 12
Study 27618389 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage according to the 5-5-5 rule (5 times per day for 5 minutes for 5 days)
Number of subjects: 20
Study 27618389 — intervention group
Group type: COMPARATOR
Intervention: No massage post-treatment
Number of subjects: 20
Study 27618389 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (massage and no massage)
Number of subjects: 20
Study 24287976 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel applied to surgical site in 6 patients.
Number of subjects: 11
Study 24287976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP gel applied) with 5 patients.
Number of subjects: 11
Study 22540912 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone (1000 mg twice daily)
Number of subjects: 699